Biogen announces FDA approval for Alprolix Biogen Idec announced that the U.S. FDA has approved Alprolix, the first recombinant, DNA derived hemophilia B therapy with prolonged circulation in the body. Alprolix is indicated for the control and prevention of bleeding episodes, perioperative management and routine prophylaxis in adults and children with hemophilia B. The therapy is shown to reduce bleeding episodes with prophylactic infusions starting at least a week apart. Alprolix was recently approved by Health Canada for the treatment of hemophilia B and is currently under review by regulatory authorities in several other countries, including Australia and Japan. Biogen Idec plans to make Alprolix commercially available to people with hemophilia B in the United States in early May.
Biogen price target lowered to $400 from $425 at Credit Suisse Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.